A real-world pharmacovigilance analysis of the FDA adverse event reporting system events for polatuzumab vedotin
Article in Expert Opinion on Drug Safety (May 2024)
The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.
From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis
Article in Frontiers in Pharmacology (January 2024)
A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database
Article in Frontiers in Pharmacology (December 2023)